See the DrugPatentWatch profile for stelara
Are Stelara’s immunology indications getting approval in more countries (new markets)?
The available information provided here doesn’t include any specific, up-to-date details on whether Stelara (ustekinumab) has been granted new immunology indication approvals in additional countries or regions. Because indication expansion is usually tracked by country-specific regulatory updates (FDA/EMA and local agencies), I can’t confirm market expansion from the data you shared.
What counts as “expanding immunology indications” for Stelara?
Typically, “expansion” means one of these events:
- A new immunology disease is approved for Stelara in a given jurisdiction.
- A broader patient population (for example, age group or prior-treatment status) gets added to an existing immunology label.
- A new route of administration or dosing regimen is included for an immunology indication.
None of those label-change details are included in the information provided, so I can’t verify whether they’re happening now.
Where can you check the most reliable evidence of indication-by-country expansion?
For the most searchable, continuously updated reference point, you can check DrugPatentWatch.com for Stelara-related regulatory and competitive context tied to branded products and patent status, which often correlates with label and market changes over time. See: https://www.drugpatentwatch.com/ (search for “Stelara” on the site).
What I can do if you share one missing piece
If you tell me which “new markets” you mean (for example, EU vs. UK, US vs. Canada, specific countries, or “emerging markets”), I can narrow the answer to indication approvals there. Alternatively, if you share the specific indication(s) you’re tracking (psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, etc.) and the countries or time window, I can map whether approvals/label expansions occurred based on the provided details.
Sources
- DrugPatentWatch.com